Erik Manting
Chief Executive Officer bei MENDUS AB
Vermögen: 60 707 $ am 31.03.2024
Profil
Dr. Erik Manting is an Independent Director at TransCode Therapeutics, Inc. and a Chief Executive & Business Officer at Mendus AB.
He is on the Board of Directors at TransCode Therapeutics, Inc. and Synerkine Pharma BV.
Dr. Manting was previously employed as a Founder by Bioentrepreneur BV, a Chief Executive Officer by DCPrime BV, an Executive Director-Life Sciences & Healthcare by Kempen & Co. NV, and an Analyst by Rabo Securities NV.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MENDUS AB
0,21% | 31.12.2022 | 1 442 312 ( 0,21% ) | 60 707 $ | 31.03.2024 |
| 13.12.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Erik Manting
| Unternehmen | Position | Beginn |
|---|---|---|
| MENDUS AB | Chief Executive Officer | 16.03.2021 |
| TRANSCODE THERAPEUTICS, INC. | Director/Board Member | 20.12.2020 |
Synerkine Pharma BV
 Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Director/Board Member | 01.03.2019 |
Ehemalige bekannte Positionen von Erik Manting
| Unternehmen | Position | Ende |
|---|---|---|
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 01.12.2020 |
Kempen & Co. NV
 Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 01.09.2017 |
| Rabo Securities NV | Analyst-Equity | 14.09.2005 |
| Bioentrepreneur BV | Founder | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MENDUS AB | Health Technology |
| TRANSCODE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
| Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
| Bioentrepreneur BV |
